CXCL13 and neoplasm: In a murine prostate cancer model, which exhibits PKCε overexpression and Pten deficiency, the release of CXCL13 by tumor cells was upregulated in a non-canonical NF-κB pathway, boosting tumor cells’ migratory properties [122].